Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velaglucerase Alfa for Bone Pathology in Type 1 Gaucher Disease
NCT02574286Phase 4Completed
- Sponsor
- Takeda
- Start
- Jun 2016
- Primary completion
- Nov 2020
- Modality
- Replacement Enzymes
- Countries
- 4
01
Overview
A Phase 4 trial of velaglucerase alfa in Gaucher disease type 1 (GD1), sponsored by Takeda. Started Jun 2016; status: completed.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on NCT02574286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574286.